Etamycin as a Novel Inhibitor.

The increase in drug-resistant , which has become resistant to existing standard-of-care agents, is a major concern, and new antibacterial agents are strongly needed. In this study, we introduced etamycin that showed an excellent activity against . We found that etamycin significantly inhibited the growth of wild-type strain, three subspecies, and clinical isolates in vitro and inhibited the growth of that resides in macrophages without cytotoxicity. Furthermore, the in vivo efficacy of etamycin in the zebrafish () infection model was greater than that of clarithromycin, which is recommended as the core agent for treating infections. Thus, we concluded that etamycin is a potential anti- candidate for further development as a clinical drug candidate.